BGPT: Paper Review: Reprogrammable bacterial nanosyringes for RNA and gene editors delivery

Explore by Goal

Quick Explanation Copied

Core idea (what they built)

The paper presents DART—a reprogrammable Photorhabdus virulence cassette (PVC) “bacterial nanosyringe” that loads RNA cargo using a U1A RNA-binding domain bound to a tandem RNA containing a U1A hairpin (9-nt loop), enabling intracellular RNA delivery and co-delivery of CRISPR components for GFP knockout in vitro and in vivo, plus a zebrafish delivery demonstration.

Long Explanation

Paper Review (science-first): Reprogrammable bacterial nanosyringes for RNA and gene editors delivery

Date provided in manuscript: October 13, 2025.

Visual figure: DART workflow (from DNA plasmids → purified PVC particles → RNA-loaded “nanosyringes” → delivery → functional readouts)

Schematic derived from the manuscript’s described strategy (PVC + U1A/tandem RNA anchoring and delivery workflows).

1) What problem is being targeted?

The authors frame the key bottlenecks for RNA therapeutics as delivery barriers, including extracellular instability/degradation and intracellular access challenges, and position PVC as a contractile injection system that can protect cargo and self-inject into recipient cells.

Critical note (skeptical framing): The paper’s main efficacy readouts for “delivery” rely heavily on fluorescence systems and do not, in the excerpt provided, include explicit quantitative measures of RNA integrity after delivery, RNA endosomal escape kinetics, biodistribution, or immunogenicity. Those gaps remain “unknowns” based on the text provided here.

2) Mechanism: how DART loads RNA into a confined PVC inner tube

The mechanistic centerpiece is: U1A RBD is fused into a PVC “Docker” component (Pd-U1A packaging/anchoring design), and tandem RNA carries a U1A-binding hairpin motif attached to a payload RNA, allowing assembly of an U1A/payload RNA complex into the PVC inner tube during self-assembly.

Key dependency/assumption: The strategy assumes that tethering by U1A hairpin is sufficient to keep RNA associated during assembly and that the delivered RNA remains functional post-injection. The evidence shown in the excerpt supports “functional fluorescence activation” and “gene editing indels,” but does not fully decompose whether failure modes arise from assembly, injection, cytosolic stability, or sequence-specific RNA folding.

3) Evidence for RNA loading and intracellular delivery (Pepper RNA → HBC530 fluorescence)

The paper uses the Pepper aptamer (~40 nt) as a fluorogenic RNA payload to detect loading/delivery, stating fluorescence is only observed when DART-delivered Pepper and the HBC530 dye are both present.

In vitro delivery quantification and cytotoxicity tradeoff: The manuscript describes a working concentration of 320 ng/μL, while higher concentrations (e.g., ~480 ng/μL) increase fluorescence but also induce obvious cell death after 24 h in A549 cells.

Intracellular localization: Confocal microscopy is used to report cytoplasmic green fluorescence after DART treatment, which the authors interpret as evidence that RNA is delivered into cells (not just stuck on membrane).

4) Modularity (“plug-and-play”): extending Pepper with siPLK1 / miR96 / gRNA

The authors claim modular payload extension at the 3′ end and report that SDS-PAGE/TEM show assembled nanosyringe structures for DART loaded with different payload RNAs (siPLK1, miR96, gRNA) and that fluorescence signals are concentration dependent upon HBC addition, with confocal microscopy (for gRNA) showing cytoplasmic fluorescence.

Critical blind spot: The excerpt does not show controls that distinguish whether different RNA payloads preserve their native folding/functional conformations after loading into PVC and after injection (beyond fluorescence activation and the downstream CRISPR readout for gRNA). If Pepper’s fluorescent activation is sensitive to local RNA structure, it could serve as an indirect proxy, but it is not a universal validator for all RNA types.

5) CRISPR co-delivery: Cas9/Cas12a protein + gRNA RNA cargo → GFP knockout

The paper describes a split strategy: PVC particles separately loaded with Cas9 or Cas12a proteins, while DART contains the gRNA; after co-addition to A549-GFP reporter cells, they claim intracellular assembly produces functional CRISPR RNPs.

Evidence reported: fluorescence microscopy showing GFP fluorescence decreases in co-delivery conditions (relative to Cas9-only or gRNA-only), flow cytometry increasing GFP-negative fraction, and high-throughput sequencing detecting indel mutations at targeted GFP loci.

6) In vivo demonstration: mouse skin GFP loss + indels

For in vivo, the authors report subcutaneous injection into transgenic mice (C57BL/6-Tg(CAG-EGFP)) with repeated administration, with imaging showing progressive GFP fluorescence loss in co-delivery groups and sequencing showing mutations at the target sites in skin genomic DNA.

Skeptical caveat: The excerpt claims “rapid clearance and safety” linked to DART hydrolysis after ~8 days, but the text provided does not include explicit biodistribution quantification, immune response markers, or longer-term histopathology timepoints. Those aspects remain important unknowns for translating “proof of concept” into safety claims.

7) Cross-species applicability: AlphaFold3 modeling + zebrafish delivery

The authors report using AlphaFold3 to model engineered PVC tail fibers fused with receptor-binding domains (AD5RGDPK7 or DARPin) and performing structural modeling across multiple model organisms, then experimentally validating GFP-loaded PVC injection in zebrafish and Pepper RNA delivery via DART in zebrafish skin (fluorescence only when both DART and HBC are present).

Interpretation risk: Binding prediction does not guarantee effective trafficking, injection probability, or functional delivery across species. The zebrafish experiment supports at least one cross-species payload/delivery case, but the “broad applicability” claim across many taxa is only partially tested experimentally within the provided excerpt.

8) Methods quality & reproducibility checks (what’s present; what’s missing)

Present in excerpt: plasmid construction approach (including co-expression in E. coli and purification by ultracentrifugation), an in vitro RNA synthesis workflow using a T7 system, structural characterization by SDS-PAGE and negative-staining TEM, and functional assays via Pepper-HBC fluorescence, confocal imaging, flow cytometry, and high-throughput sequencing with CRISPResso2.

Missing/unclear from what was provided: details of exact RNA sequences and complete gRNA/payload tandem designs are referenced as “Supplementary Tables,” which are not included in the supplied text. Without those, reproducing “plug-and-play” payload claims is harder.

9) Main strengths vs main concerns (balanced, skeptical)

Strengths

Conceptual modularity: U1A-based RNA anchoring inside PVC and a “plug-and-play” extension claim are supported by multiple payload types and multiple readouts (fluorescence delivery proxy; CRISPR functional proxy for gRNA).
Functional validation: The shift from “delivery” to “genome editing” is supported by fluorescence loss and indel detection at target loci in vitro and in vivo.
Cross-species exploration: Zebrafish validation is included, and computational structural modeling is used to rationalize receptor targeting.

Concerns / unknowns

Delivery vs RNA integrity: Fluorescence activation implies RNA presence and suitable conformational compatibility, but does not fully establish RNA integrity kinetics or nuclease resistance beyond that proxy.
Safety claims are partially supported: Cytotoxicity in vitro at higher doses is noted, and DART hydrolysis after ~8 days is described, but broader safety endpoints (immune responses, systemic biodistribution) are not evidenced in the excerpt.
Cross-species generality may be overextended: AlphaFold3 binding predictions are followed by experimental zebrafish validation, but the “broad applicability” across many taxa remains partly computational without extensive experimental confirmation in the excerpt.

Buttons for author-focused deep dives (BGPT Author Reviews)

Feedback:

Updated: April 07, 2026